Computational study of SARS-CoV-2 3CLpro/RdRp-C60 fullerene complexes binding properties

被引：0
|
作者：
Hurmach, V. [1 ]
Platonov, M. [2 ]
Prylutskyy, Yu. [1 ]
机构：
[1] Taras Shevchenko Natl Univ Kyiv, Kiev, Ukraine
[2] Inst Mol Biol & Genet, Kiev, Ukraine
来源：
EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS | 2021年 / 50卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P-226
引用
收藏
页码：158 / 158
页数：1
相关论文
共 50 条
  • [21] Black tea bioactives as inhibitors of multiple targets of SARS-CoV-2 (3CLpro, PLpro and RdRp): a virtual screening and molecular dynamic simulation study
    Gogoi, Madhurjya
    Borkotoky, Meghali
    Borchetia, Sangeeta
    Chowdhury, Pritom
    Mahanta, Saurav
    Barooah, Anoop Kumar
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (15): : 7143 - 7166
  • [22] Progress on SARS-CoV-2 3CLpro Inhibitors: Inspiration from SARS-CoV 3CLpro Peptidomimetics and Small-Molecule Anti-Inflammatory Compounds
    Zhu, Jiajie
    Zhang, Haiyan
    Lin, Qinghong
    Lyu, Jingting
    Lu, Lu
    Chen, Hanxi
    Zhang, Xuning
    Zhang, Yanjun
    Chen, Keda
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2022, 16 : 1067 - 1082
  • [23] A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study
    Jurica Novak
    Vladimir A. Potemkin
    Molecular Diversity, 2022, 26 : 2631 - 2645
  • [24] The reactivity of cysteines of 3CLpro affects the oligomerization state of the Sars-CoV-2 protease
    Cipollone, I.
    Iacobucci, I.
    Cozzolino, F.
    Morasso, S.
    Storici, P.
    Iaconis, D.
    Talarico, C.
    Manelfi, C.
    Beccari, A.
    Monti, M.
    FEBS OPEN BIO, 2024, 14 : 422 - 422
  • [25] Sub-Micromolar Inhibition of SARS-CoV-2 3CLpro by Natural Compounds
    Rizzuti, Bruno
    Ceballos-Laita, Laura
    Ortega-Alarcon, David
    Jimenez-Alesanco, Ana
    Vega, Sonia
    Grande, Fedora
    Conforti, Filomena
    Abian, Olga
    Velazquez-Campoy, Adrian
    PHARMACEUTICALS, 2021, 14 (09)
  • [26] Discovery of natural catechol derivatives as covalent SARS-CoV-2 3CLpro inhibitors
    Wang, Feng
    Liu, Donglan
    Gao, Dingding
    Yuan, Jinwei
    Zhao, Jingxian
    Yuan, Shuai
    Cen, Yixin
    Lin, Guo-Qiang
    Zhao, Jincun
    Tian, Ping
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2024, 264
  • [27] Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CLpro
    Ma, Ling
    Li, Quanjie
    Xie, Yongli
    Zhao, Jianyuan
    Yi, Dongrong
    Guo, Saisai
    Guo, Fei
    Wang, Jing
    Yang, Long
    Cen, Shan
    ANTIVIRAL RESEARCH, 2022, 207
  • [28] In silico analysis of echinocandins binding to the main proteases of coronaviruses PEDV (3CLpro) and SARS-CoV-2 (Mpro)
    Gérard Vergoten
    Christian Bailly
    In Silico Pharmacology, 9 (1)
  • [29] Human Superantibodies to 3CLpro Inhibit Replication of SARS-CoV-2 across Variants
    Glab-ampai, Kittirat
    Kaewchim, Kanasap
    Saenlom, Thanatsaran
    Thepsawat, Watayagorn
    Mahasongkram, Kodchakorn
    Sookrung, Nitat
    Chaicumpa, Wanpen
    Chulanetra, Monrat
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (12)
  • [30] A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study
    Novak, Jurica
    Potemkin, Vladimir A.
    MOLECULAR DIVERSITY, 2022, 26 (05) : 2631 - 2645
12345